Screening and surveillance of hepatocellular carcinoma by serum des‐gamma‐carboxy prothrombin in patients with glycogen storage disease type Ia
A. B. Schreuder,
R. J. Overduin,
N. C. Peltenburg,
L. deBoer,
F. A. J. A. Bodewes,
T. G. J. Derks
Affiliations
A. B. Schreuder
Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands
R. J. Overduin
Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands
N. C. Peltenburg
Department of Metabolic Diseases and internal medicine Erasmus Medical Center Rotterdam The Netherlands
L. deBoer
Department of Metabolic Diseases, Amalia Children's Hospital Radboud University Medical Center Nijmegen The Netherlands
F. A. J. A. Bodewes
Department of Pediatric Hepatology and Gastroenterology, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands
T. G. J. Derks
Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands
Abstract No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha‐fetoprotein and carcino‐embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des‐gamma‐carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.
